Floatz logo

WARFARIN

Cerebral Embolism and Thrombosis

Massachusetts General HospitalSmall moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

21 Active assets in the Cerebral Embolism and Thrombosis cohort.

Asset / SponsorPhaseRating
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
Asan Medical Center
Phase 4BBB
Acetylsalicylic Acid
Sclnow Biotechnology Co., Ltd.
Phase 4BBB
Sovateltide
Pharmazz, Inc.
Phase 4BBB
Plavix
The Second Hospital of Anhui Medical University
Phase 4BBB
Human Urinary Kallidinogenase
Huisheng Chen
Phase 4BB

View all 50 →

Same molecule, other indications

WARFARIN is also rated in:

venous thromboembolismDormant
A
Indicative ·
81 / 100
View asset →
atrial fibrillationDormant
BBB
Indicative ·
77 / 100
View asset →
hemorrhagic diseaseDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →